Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 |Industry: Healthcare Services
|Expensive Star

Dr. Lal Pathlabs Ltd.    
28 Oct 2021


  • Revenue: Rs 498.4 Cr, a growth of 15.4%
  •  Normalised EBITDA at Rs 152.2 Cr with margin at 30.5%
  • PBT at Rs 130.7 Cr with margin at 26.2%, and
  • PAT Rs 96.3 Cr with margin at 19.3%
  • Operating Revenue increased by 15.4% in Q2 FY22 to Rs. 498.4 Cr vs Rs 431.9 Cr in Q2 FY21
  • Covid and Allied contributed 10.1% to Revenue in Q2 FY22 with 4.7 lac RT-PCR tests
  • Normalised EBITDA (after adjustment for stock based compensation & CSR cost) for Q2 FY22 is at Rs. 152.2 Cr vs Rs 134.7 Cr in the same quarter last year
  • PBT is at Rs 130.7 Cr in Q2 FY22 vs Rs 116.6 Cr. in Q2 last year
  • Profit after Tax in Q2 FY22 at Rs. 96.3 Cr as compared to Rs 87.1 Cr in Q2 last year

“Our joining hands with Suburban Diagnostics is a significant step in LPL’s endeavor to expand our footprint in Western India. I am confident that our combined strengths and a similar DNA of both the companies- led by doctor promoters, will lead to new heights in serving our customers across Western India.” (Hony) Brig. Dr Arvind Lal, Padma Shri, Executive Chairman, Dr Lal PathLabs Limited

“Suburban Diagnostics transaction is in line with our stated strategy of driving growth through inorganic route especially in West and South regions. This transaction has a strategic significance for us from a long term stand point.” Dr. Om Manchanda, Managing Director, Dr Lal PathLabs Limited

Result PDF

Dr. Lal Pathlabs Ltd.'s price crossed above SMA100 today
More from Dr. Lal Pathlabs Ltd.